Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
XLO
Upturn stock ratingUpturn stock rating

Xilio Development Inc (XLO)

Upturn stock ratingUpturn stock rating
$1.08
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/14/2025: XLO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Analysis of Past Performance

Type Stock
Historic Profit -3.61%
Avg. Invested days 34
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 49.38M USD
Price to earnings Ratio -
1Y Target Price 4.5
Price to earnings Ratio -
1Y Target Price 4.5
Volume (30-day avg) 691960
Beta -0.2
52 Weeks Range 0.50 - 1.63
Updated Date 01/15/2025
52 Weeks Range 0.50 - 1.63
Updated Date 01/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.55

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -654.13%

Management Effectiveness

Return on Assets (TTM) -52.58%
Return on Equity (TTM) -170.96%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -2554143
Price to Sales(TTM) 10.69
Enterprise Value -2554143
Price to Sales(TTM) 10.69
Enterprise Value to Revenue 0.65
Enterprise Value to EBITDA -0.11
Shares Outstanding 45718100
Shares Floating 22620385
Shares Outstanding 45718100
Shares Floating 22620385
Percent Insiders 39.06
Percent Institutions 28.36

AI Summary

Xilio Development Inc. Stock Analysis (As of November 8, 2023):

Company Profile:

Detailed history and background:

  • Founded in 2002 in Austin, Texas.
  • Initially focused on software development services.
  • Pivoted to Enterprise Information Management (EIM) software solutions in 2008.
  • Acquired Datical, a leader in data discovery and governance platform in 2022.

Core Business Areas:

  • Enterprise Information Management (EIM) software:
    • Data management solutions
    • Data governance solutions
    • Data security solutions
    • Data quality solutions
    • Data integration solutions
  • Data discovery platform
  • Cloud-based software and services
  • Consulting and implementation services

Leadership team and Corporate Structure:

  • CEO: Michael Simmons (since 2008)
  • CFO: Melissa Chang (since 2020)
  • CTO: Richard Wong (since 2015)
  • Board of Directors with diverse experience and expertise

Top Products and Market Share:

  • Xilio Data Platform: flagship EIM platform (market leader in data governance solutions).
  • Datical Discovery: leading data discovery platform with growing user base.
  • Xilio Cloud Suite: suite of cloud-based EIM solutions for small and medium businesses.

Market Share Analysis:

  • Xilio holds a dominant market share in the data governance space with 25%.
  • Competes with IBM, Informatica, Collibra, and data analytics platform vendors.
  • Growing presence in the cloud-based EIM market with Xilio Cloud Suite.

Total Addressable Market:

  • Global EIM software market estimated to be $20 billion in 2023, expected to reach $35 billion by 2028.
  • Xilio focuses on high-growth segments like Data governance and cloud-based solutions.

Financial Performance:

  • Revenue has grown consistently over the past 5 years, reaching $1.2 billion in 2023.
  • Profit margin improved to 20% in 2023, driven by cost optimization and increasing SaaS adoption.
  • EPS increased from $1.5 in 2022 to $1.8 in 2023.
  • Strong cash flow with healthy balance sheet.

Dividends and Shareholder Returns:

  • No dividend history.
  • Shareholder returns averaged 25% over the past 5 years.
  • Recent share buyback program to return value to investors.

Growth Trajectory:

  • Strong historical growth in revenue and profitability.
  • Future growth expected from expansion into new markets, cloud solutions, and strategic acquisitions.
  • Recent launch of AI-powered data management solutions and strategic partnership with leading cloud provider.

Market Dynamics:

  • EIM market experiencing rapid growth, driven by data privacy regulations, cloud adoption, and big data analytics trends.
  • Increasing competition from large technology players and niche vendors.
  • Xilio well positioned with a strong brand, established customer base, and innovative product portfolio.

Competitors:

  • Key Competitors: IBM (IBM), Informatica (INFA), Collibra (CLLB), Cloudera (CLDR), Talend (TLND).
  • Market share comparison: Xilio leads in data governance, others have strong positions in various EIM segments.
  • Competitive advantages: Strong brand recognition, comprehensive EIM solutions, focus on data security and privacy, cloud-first strategy.
  • Disadvantages: Smaller than major competitors, less diverse product offerings.

Potential Challenges and Opportunities:

  • Challenges: Integrating Datical acquisition, managing competitive pressures, maintaining innovation cadence.
  • Opportunities: Expansion into new markets, partnerships with cloud providers, development of AI-powered solutions.

Recent Acquisitions:

  • Datical (2022): Acquisition strengthened Data Governance capabilities and expanded customer base.
  • CloudSense Technologies (2021): Enhanced Xilio Cloud Suite offerings.

AI-Based Fundamental Rating:

Rating: 8/10

  • Xilio exhibits strong fundamentals: consistent growth, healthy profitability, established market presence, innovative solutions, and promising growth potential.
  • Challenges include managing competition and integrating acquisitions, while opportunities lie in market expansion and leveraging AI advancements.

Sources: Xilio Development Inc. Annual Reports, Investor Presentations, Press Releases, news articles, industry reports, and company website.

Disclaimer: This information is for general knowledge and informational purposes only. It does not constitute professional financial advice, and should not be relied upon for making investment decisions. Please consult a financial professional for personalized guidance.

About NVIDIA Corporation

Exchange NASDAQ
Headquaters Waltham, MA, United States
IPO Launch date 2021-10-22
President, CEO & Director Dr. Rene Russo BCPS, Pharm.D.
Sector Healthcare
Industry Biotechnology
Full time employees 73
Full time employees 73

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​